CONTRAINDICATION
AURYXIA ® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis
WARNINGS AND PRECAUTIONS
Iron Overload: Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores.
ADVERSE REACTIONS
The most common adverse reactions reported with AURYXIA in clinical trials were:
SPECIFIC POPULATIONS
Pregnancy and Lactation: There are no available data on AURYXIA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, an overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation.
What is auryxia used for?
Auryxia (ferric citrate) is a member of the phosphate binders drug class and is commonly used for Hyperphosphatemia of Renal Failure, and Iron Deficiency Anemia.
Is Auryxia a generic?
Auryxia is available as a brand name drug only, a generic version is not yet available. For more information, read about generic Auryxia availability . This Auryxia price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
Hyperphosphatemia (HP)
For the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis 1
Iron deficiency anemia (IDA)
For the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis 1
